Fierce Pharma
Fierce Biotech
Fierce Healthcare
Fierce Life Sciences Events
Advertise
About Us
Biotech
Cell & Gene Therapy
Clinical Data
Venture Capital
Deals
Research
Medtech
Devices
Diagnostics
AI and Machine Learning
CRO
Special Reports
Fierce 50
Special Report
Awards Gala
Resources
Fierce Events
Industry Events
Webinars
Podcasts
Whitepapers
Survey
Events
Subscribe
Subscribe
Biotech
Cell & Gene Therapy
Clinical Data
Venture Capital
Deals
Research
Medtech
Devices
Diagnostics
AI and Machine Learning
CRO
Special Reports
Fierce 50
Special Report
Awards Gala
Resources
Fierce Events
Industry Events
Webinars
Podcasts
Whitepapers
Survey
Events
Subscribe
Fierce Pharma
Fierce Biotech
Fierce Healthcare
Fierce Life Sciences Events
Advertise
About Us
cholesterol drug
Biotech
Verve shows base editing works in humans—and sees stock sink
Verve has published the first data on an in vivo base editing program in humans, but investors pummeled the stock amid potential safety concerns.
Nick Paul Taylor
Nov 13, 2023 8:43am
LIB's cholesterol-busting drug hits goal in 2nd phase 3 trial
Aug 29, 2023 6:30am
Merck bets big on oral PCSK9 inhibitor with phase 3 program
Aug 25, 2023 8:35am
Cholesterol-focused Esperion loses appetite for Serometrix pact
Aug 1, 2023 10:46am
NewAmsterdam's Amgen castoff cuts LDL cholesterol in phase 2
Jan 17, 2023 9:15am
23andMe lands new label for cholesterol drug response report
Oct 27, 2022 11:12am